{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-092005","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2026-08-06T20:11:30+00:00","discovered_at":"2026-08-06T20:13:00.710960+00:00","generated_at":"2026-08-06T20:15:47.368074+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CVRx Q2 revenue $15.7M (+16% YoY); lowers FY2026 revenue guidance to $58-60M","bullets":["Net loss $14.0M ($0.53/share) vs $14.7M ($0.57) in Q2 2025; cash $64.6M.","U.S. revenue $14.8M (+21% YoY) on 466 units; active implanting centers grew to 258.","Humana issued Medicare Advantage coverage policy for Barostim, effective May 1, 2026.","FY2026 guidance: total revenue $58-60M, gross margin 86-87%, operating expenses $99-101M.","Q3 2026 revenue expected between $13.5M and $14.5M; cites sales territory and payer headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-092005","json":"https://secwatch.observer/filing/0001104659-26-092005.json","markdown":"https://secwatch.observer/filing/0001104659-26-092005.md","text":"https://secwatch.observer/filing/0001104659-26-092005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926092005/0001104659-26-092005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926092005/tm2622361d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:15:47.368074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}